REMARKS / ARGUMENTS

In response to the restriction requirement under 35 USC 121 and 372, Applicants elect the claims of Group II, claims 1-9, 11-16 and 19 drawn to a method of treatment. As single disclosed species of compound, Applicants elect midostaurin, also known as PKC412, which is disclosed on page 31 of the specification. Mastocytosis is elected as the particular disorder or condition.

Entry of this response is requested and an action on the merits is awaited.

Novartis Pharmaceuticals Corp. Patents Pharma One Health Plaza, Building 104 East Hanover, NJ 07936-1080 (862) 778-7824

Date: March 5, 2009

Respectfully submitted,

George R. Dohmann Attorney for Applicant Reg. No. 33,593

_